http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Baxter to Host Third-Quarter 2022 Financial Results Conference Call for Investors
-
Baxter Expands Historically Black Colleges and Universities Partnerships, Funding Commitments to Further the Pipeline of Black Healthcare Professionals
-
Baxter (BAX) Granted US FDA 510(k) Clearance of Novum IQ Syringe Infusion Pump
-
Baxter Announces U.S. FDA Clearance of Novum IQ Syringe Infusion Pump with Dose IQ Safety Software
-
Baxter to Present at the 2022 Wells Fargo Healthcare Conference
-
Baxter to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
-
Baxter Broadens Efforts to Increase Awareness, Education and Support of Kidney Health in Black Communities
-
Baxter Reports Second-Quarter 2022 Results
-
Baxter Declares Quarterly Dividend
-
Baxter Details Progress Toward Environmental, Social and Governance (ESG) Priorities in Annual Corporate Responsibility Report
-
Baxter to Host Second-Quarter 2022 Financial Results Conference Call for Investors
-
Baxter to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
-
Baxter Highlights Business Strategies and Innovation at 2022 Investor Conference
-
Baxter to Host 2022 Investor Conference
-
Baxter Increases Dividend and Declares Quarterly Dividend
-
Baxter Reports First-Quarter 2022 Results
-
Baxter Highlights New Data at SCCM Critical Care Congress Showing Hemodynamic Monitoring May Help Predict Patient Outcomes
-
Baxter (BAX) Announces U.S. FDA Clearance of ST Set Used to Help Treat Acute Kidney Injury Patients in the Hospital
-
Baxter Announces U.S. FDA Clearance of ST Set Used to Help Treat Acute Kidney Injury Patients in the Hospital
-
Pre-Open Stock Movers 04/04: (RCAT) (TWTR) (GGPI) Higher; (DWAC) (OCGN) (SBUX) Lower (more...)
-
Baxter to Host First-Quarter 2022 Financial Results Conference Call for Investors
-
Fast Radius Expands Leadership Team and Appoints New General Counsel and Chief Accounting Officer
-
Baxter to Present at the Barclays Global Healthcare Conference
-
Baxter Presents Data Indicating Sharesource Increases Patients’ Time on Home Dialysis by More Than Three Months
-
Baxter Expands Cybersecurity Commitment, Joins Forces With U.S. Cybersecurity and Infrastructure Security Agency (CISA) Led Program
-
Baxter to Present at the Raymond James 43rd Annual Institutional Investors Conference
-
Baxter Reports Fourth-Quarter and Full-Year 2021 Results
-
Baxter Declares Quarterly Dividend
-
Baxter to Present at Citi’s 2022 Virtual Healthcare Conference
-
Baxter to Host Fourth-Quarter 2021 Financial Results Conference Call for Investors
-
Baxter Completes Acquisition of Hillrom, Creating ~$15 Billion Global Medtech Leader
-
Baxter Presents Data at ASHP Meeting Indicating Machine Learning May Enhance Infusion Pump Programming Safety
-
Baxter Declares Quarterly Dividend
-
Baxter Named to Dow Jones Sustainability Indices in Recognition of Continued Commitment to Corporate Responsibility
-
Baxter (BAX) Announces $100 Million Investment in BioPharma Solutions Halle/Westfalen, Germany Sterile Fill/Finish Manufacturing Facility
-
Baxter Announces $100 Million Investment in BioPharma Solutions Halle/Westfalen, Germany Sterile Fill/Finish Manufacturing Facility
-
Baxter Highlights New Data Indicating Sharesource Digital Health Platform for Home Dialysis May Improve Survival and Reduce Hospitalizations
-
Baxter to Present at Evercore ISI 4th Annual HealthCONx Conference
-
Baxter Reports Third-Quarter 2021 Results
-
Baxter and bioMérieux Announce CE Mark for NEPHROCLEAR™ CCL14 Test to Predict Persistent Severe Acute Kidney Injury
-
Baxter to Present at Credit Suisse 30th Annual Virtual Healthcare Conference
-
Baxter Presents Critical Care Data at 34th Annual European Society of Intensive Care Medicine LIVES Congress
-
Baxter to Host Third-Quarter 2021 Financial Results Conference Call for Investors
-
Baxter (BAX) Announces U.S. FDA Approval and Launch of Ready-to-use Cardiovascular Medicine Norepinephrine in Premix Formulation
-
Baxter Announces U.S. FDA Approval and Launch of Ready-to-use Cardiovascular Medicine Norepinephrine in Premix Formulation
-
Baxter (BAX) Acquires Hillrom (HRC) for $156/sh or $12.4B Including Debt
-
Baxter to Acquire Hillrom, Expanding Connected Care and Medical Innovation Globally
-
Miromatrix Announces Key Strategic Investors to Advance the Development of Bioengineered Livers and Kidneys
-
Miromatrix Announces Key Strategic Investors to Advance the Development of Bioengineered Livers and Kidneys
-
Baxter Advances Enterprise Digital Transformation in Collaboration With AWS

